JP2020520923A5 - - Google Patents

Download PDF

Info

Publication number
JP2020520923A5
JP2020520923A5 JP2019563592A JP2019563592A JP2020520923A5 JP 2020520923 A5 JP2020520923 A5 JP 2020520923A5 JP 2019563592 A JP2019563592 A JP 2019563592A JP 2019563592 A JP2019563592 A JP 2019563592A JP 2020520923 A5 JP2020520923 A5 JP 2020520923A5
Authority
JP
Japan
Prior art keywords
item
compound
paclitaxel
items
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019563592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032937 external-priority patent/WO2018213424A1/en
Publication of JP2020520923A publication Critical patent/JP2020520923A/ja
Publication of JP2020520923A5 publication Critical patent/JP2020520923A5/ja
Pending legal-status Critical Current

Links

JP2019563592A 2017-05-17 2018-05-16 がんを処置するための方法 Pending JP2020520923A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507353P 2017-05-17 2017-05-17
US62/507,353 2017-05-17
PCT/US2018/032937 WO2018213424A1 (en) 2017-05-17 2018-05-16 Methods for treating cancer

Publications (2)

Publication Number Publication Date
JP2020520923A JP2020520923A (ja) 2020-07-16
JP2020520923A5 true JP2020520923A5 (enExample) 2021-07-26

Family

ID=62567800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563592A Pending JP2020520923A (ja) 2017-05-17 2018-05-16 がんを処置するための方法

Country Status (5)

Country Link
US (1) US10646464B2 (enExample)
JP (1) JP2020520923A (enExample)
CA (1) CA3062656A1 (enExample)
TW (1) TW201906602A (enExample)
WO (1) WO2018213424A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
TW202102207A (zh) * 2019-03-27 2021-01-16 新加坡商新加坡保健服務集團有限公司 對於癌病具有治療意義的生物標記

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS63196576A (ja) 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
DE69131033T2 (de) 1990-07-10 1999-11-18 Canon K.K., Tokio/Tokyo Lichtempfindliches elektrophotographisches Element
TW252136B (enExample) 1992-10-08 1995-07-21 Ciba Geigy
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EP1146869A2 (en) 1999-01-27 2001-10-24 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
EP1897540A3 (en) 1999-01-27 2008-07-23 University Of South Florida Inhibition of STAT3 signal transduction for human cancer therapy
AU777572B2 (en) 1999-04-01 2004-10-21 Board Of Regents, The University Of Texas System Compositions and methods for treating lymphoma
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
CA2386793C (en) 1999-08-02 2006-03-28 F. Hoffmann-La Roche Ag New selective retinoid agonists
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
AU9399501A (en) 2000-10-09 2002-04-22 Isis Innovation Therapeutic antibodies
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US7998947B2 (en) 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
WO2003045357A1 (en) 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US20030139466A1 (en) 2001-11-29 2003-07-24 Peritt David L. Methods for pretreating a subject with extracorporeal photopheresis
JP2005526084A (ja) 2002-03-15 2005-09-02 ナットイムネ・アクティーゼルスカブ マンノース結合レクチンを含む医薬組成物
ES2401428T3 (es) 2002-04-10 2013-04-19 Genentech, Inc. Variantes de anticuerpos anti-HER2
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
KR20110025885A (ko) 2002-07-15 2011-03-11 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염을 치료하는데 있어서 이의 용도
US20060142271A1 (en) 2002-09-17 2006-06-29 Klaus Muller Novel lapacho compounds and methods of use thereof
WO2004035607A2 (en) 2002-10-17 2004-04-29 Genmab A/S Human monoclonal antibodies against cd20
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
TWI323662B (en) 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
KR101531400B1 (ko) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP4804357B2 (ja) 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗ｃｄ５２抗体
WO2005056055A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF PROTECTING AGAINST RADIATION USING INDUCERS OF NF-κB
PT1701941E (pt) 2003-12-11 2012-08-03 Univ Texas Compostos para o tratamento de doenças proliferativas celulares
DE10359828A1 (de) 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
CA2563305A1 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
JP2008505112A (ja) 2004-07-02 2008-02-21 イコス・コーポレイション Ｃｈｋ１の阻害に有用な化合物
AU2005287404B2 (en) 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
CN101023086A (zh) 2004-08-18 2007-08-22 阿斯利康(瑞典)有限公司 选择性稠合的杂环及其应用
WO2006052712A1 (en) 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
US7951374B2 (en) 2004-12-14 2011-05-31 University Of South Florida Methods for inhibiting STAT3 signaling in immune cells
WO2006071812A2 (en) 2004-12-23 2006-07-06 H. Lee Moffitt Cancer Center And Research Institute Platinum iv complex inhibitor
CN101511179A (zh) 2005-02-25 2009-08-19 密执安州立大学董事会 Stat3的小分子抑制剂及其用途
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
US20070009532A1 (en) 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
CA2628728A1 (en) 2005-12-24 2007-07-05 Biotica Technology Ltd. 21-deoxymacbecin analogues useful as antitumor agents
WO2007087129A2 (en) 2006-01-12 2007-08-02 Merck & Co., Inc. Fluorinated arylamide derivatives
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070243192A1 (en) 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
JP2009527508A (ja) 2006-02-24 2009-07-30 メルク フロスト カナダ リミテツド ２−（フェニル又は複素環）−１ｈ−フェナントロ［９，１０−ｄ］イミダゾール
BRPI0709916B8 (pt) 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
ES2873350T3 (es) 2007-08-27 2021-11-03 1Globe Health Inst Llc Composiciones de ARN interferente asimétrico y usos de las mismas
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
US20100297118A1 (en) 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
US8267122B2 (en) 2009-06-30 2012-09-18 Ge Aviation Systems Llc Method and systems for bleed air supply
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CN103002890A (zh) 2010-03-19 2013-03-27 波士顿生物医学公司 靶向癌症干细胞的新的化合物和组合物
SG10201704745UA (en) 2010-03-19 2017-07-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
CN103025159A (zh) 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
JP5208239B2 (ja) 2010-09-29 2013-06-12 タヒボジャパン株式会社 アルキンカップリングによる抗がん活性三環式化合物の新規製法
EP2681203A4 (en) 2011-03-04 2014-07-30 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd NOVEL 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANS ESTERS FOR THERAPEUTIC TREATMENT OF DISEASES
US9220776B2 (en) 2011-03-31 2015-12-29 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2013172918A1 (en) 2012-05-15 2013-11-21 University Of Southern California Ksr1 gene polymorphism for use in predicting outcome and therapy selection
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
JP6199787B2 (ja) 2014-03-28 2017-09-20 京セラドキュメントソリューションズ株式会社 画像形成装置
DK3043778T3 (da) 2013-09-13 2017-11-27 Bayer Pharma AG Farmaceutiske sammensætninger, der indeholder refametinib
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
WO2015190489A1 (ja) 2014-06-09 2015-12-17 京都薬品工業株式会社 新規抗癌剤
JP2016016973A (ja) 2014-07-10 2016-02-01 株式会社リコー シート処理装置
WO2016030455A1 (en) 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
CA2944085C (en) 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
CA2980845A1 (en) 2015-03-27 2016-10-06 Boston Biomedical, Inc. Water-soluble prodrugs
HK1250942A1 (zh) 2015-04-17 2019-01-18 Boston Biomedical, Inc. 用於治疗癌症的方法
SG11201708505WA (en) 2015-04-17 2017-11-29 Boston Biomedical Inc Methods for treating cancer
SG11201708504XA (en) 2015-04-17 2017-11-29 Boston Biomedical Inc Methods for treating cancer
CA2983468A1 (en) 2015-04-27 2016-11-03 Boston Biomedical, Inc. Stat3 compounds and kinase inhibitors for the treatment of cancer
EA201792623A1 (ru) 2015-06-03 2018-04-30 Бостон Биомедикал, Инк. Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
WO2017013865A1 (ja) 2015-07-17 2017-01-26 大日本住友製薬株式会社 ２－アセチル－４Ｈ，９Ｈ－ナフト［２，３－ｂ］フラン－４，９－ジオンの製造方法
JP2019506392A (ja) 2016-01-20 2019-03-07 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
JP6936214B2 (ja) 2016-03-25 2021-09-15 大日本住友製薬株式会社 ２−アルキルカルボニルナフト［２，３−ｂ］フラン−４，９−ジオンの関連物質の製造方法、及びその関連物質
US20190375723A1 (en) 2016-11-22 2019-12-12 Boston Biomedical, Inc. New Naphtho[2,3-B]Furan Derivatives
CA3058162A1 (en) 2017-03-30 2018-10-04 Boston Biomedical, Inc. Compositions for treating and/or preventing cancer
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
JP2019110987A (ja) 2017-12-21 2019-07-11 オムロンヘルスケア株式会社 測定装置およびプログラム

Similar Documents

Publication Publication Date Title
JP2020520923A5 (enExample)
Medikonda et al. A review of glioblastoma immunotherapy
Maxwell et al. Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system
Shahid et al. Immunotherapy and targeted therapy—the new roadmap in cancer treatment
Stinchcombe et al. Current treatments for advanced stage non–small cell lung cancer
JP2019506392A5 (enExample)
JP2009514881A5 (enExample)
Lloyd-Jones Niacin and HDL cholesterol–time to face facts
JP2019507721A5 (enExample)
JP2016525097A5 (enExample)
JP2016510748A5 (enExample)
JP2016513097A5 (enExample)
JP2015532292A5 (enExample)
JP2010514787A5 (enExample)
JP2017529382A5 (enExample)
JP2018525358A5 (enExample)
JP2018522045A5 (enExample)
JP2018511643A5 (enExample)
JP2017533220A5 (enExample)
JP2020512977A5 (enExample)
EP3866804A1 (en) Combinations for immune-modulation in cancer treatment
JP2020516663A5 (enExample)
JP6116481B2 (ja) 神経内分泌腫瘍を治療する方法
Dietrich et al. BRAF inhibitor therapy in HCL
JP2021505669A5 (enExample)